Biotech company Pharming Group NV ( Pharming or the Company ) today announced that following the announcement by Pharming and Santarus on November 7, 2012 that the pivotal Phase III clinical study of RUCONEST (recombinant human C1 esterase
inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met its primary endpoint, and in accordance with the terms of the license agreement between Pharming and Santarus, a US$10 million milestone has now been paid to Pharming.
Publication Describes Safety and Efficacy Profile of Cinryze (C1 esterase
inhibitor[human]) in Children and Adolescents Receiving 2,237 Infusions -
Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute laryngeal, facial and abdominal attacks of hereditary angioedema (HAE).
ViroPharma Incorporated (NASDAQ: VPHM) today announced that data relating to Cinryze(R) (C1 esterase
inhibitor [human]) from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.
19, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated its Phase 2b double blind, multicenter, dose ranging study to evaluate the safety and efficacy of subcutaneous (SC) administration of Cinryze (C1 esterase
inhibitor[human)] in combination with Halozyme's Enhanze (TM) technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in adolescents and adults with hereditary angioedema (HAE) for prevention of HAE attacks.
ViroPharma commercializes Cinryze(R) (C1 esterase
inhibitor [human]) in the U.
inhibitor[human]) at doses up to 2500 units in patients with hereditary angioedema (HAE).
DUBAI, United Arab Emirates, December 6, 2010 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced data in five poster presentations relating to Cinryze(R) (C1 esterase
inhibitor [human]) at the 2010 International Scientific Conference of the World Allergy Organization (WAO), December 5 through 8 in Dubai, UAE.
The condition is caused by a genetic deficiency of C1 esterase
inhibitor (C1-INH), a naturally occurring molecule that inhibits kallikrein and other serine proteases in the blood.
inhibitor[human]) demonstrating that ViroPharma's Path to Independence (TM) program, a self-administration training and support program for hereditary angioedema (HAE) patients receiving prophylactic Cinryze, positively impacts the site of care in favor of home/self-administration as well as adherence to routine preventive therapy.
The study, "Human C1 Esterase
Inhibitor (C1-INH) Substitution in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks," is expected to begin in the third quarter of this year under an FDA-approved protocol.
ViroPharma commercializes Cinryze(TM) (C1 esterase
inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).